Infectious diseases research and clinical practice continue to evolve rapidly, driven by emerging pathogens, antimicrobial resistance, and advances in ...
Immuron Limited announced the submission of the Clinical Study Report for its Phase 2 clinical trial of Travelan® (IMM-124E) to the FDA, which demonstrated statistically significant immunological and ...
On this episode of "The Top Line," Fierce Biotech's James Waldron and Fierce Pharma's Fraiser Kansteiner discuss the clinical trial failures that stood out in 2025 and what they suggest about the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results